• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Cystic Fibrosis Market 2015-2022 - Global Strategic Business Report 2017 - FDA Approves Vertex's ORKAMBI - Research and Markets

    Cystic Fibrosis Market 2015-2022 - Global Strategic Business Report 2017 - FDA Approves Vertex's ORKAMBI - Research and Markets

  2. Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties

    Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties

  3. UPDATE: Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties

    UPDATE: Here's a closer look at FDA commissioner nominee Scott Gottlieb's significant corporate ties

  4. Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

    Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

  5. Health Care Down As Traders Hedge On Policy Outlook - Health Care Roundup

    Health Care Down As Traders Hedge On Policy Outlook - Health Care Roundup

  6. Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Update

    Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Update

  7. New Pressure on Drug Giant -- WSJ

    New Pressure on Drug Giant -- WSJ

  8. The Year is U.S. Equity Funds

    Domestic stocks have proved resilient in a tumultuous 2016.

  9. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  10. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

123

©2017 Morningstar Advisor. All right reserved.